WO2002088366A1 - Enzyme de clivage du facteur de von willebrand (vwf) - Google Patents
Enzyme de clivage du facteur de von willebrand (vwf) Download PDFInfo
- Publication number
- WO2002088366A1 WO2002088366A1 PCT/JP2002/004141 JP0204141W WO02088366A1 WO 2002088366 A1 WO2002088366 A1 WO 2002088366A1 JP 0204141 W JP0204141 W JP 0204141W WO 02088366 A1 WO02088366 A1 WO 02088366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vwf
- sequence
- enzyme
- amino acid
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02722783A EP1391516A4 (en) | 2001-04-25 | 2002-04-25 | VON WILLEBRAND FACTOR (VWF) COLUMN ENZYM |
CA2445421A CA2445421C (en) | 2001-04-25 | 2002-04-25 | Von willebrand factor (vwf)-cleaving protease |
JP2002585646A JP4163517B2 (ja) | 2001-04-25 | 2002-04-25 | フォンビルブラント因子(vWF)切断酵素 |
US10/475,538 US7112666B2 (en) | 2001-04-25 | 2002-04-25 | Von Willebrand Factor (Vwf)-cleaving protease |
KR1020037014013A KR101047604B1 (ko) | 2001-04-25 | 2002-04-25 | 폰 빌브란트 인자(vWF)-절단 효소 |
US11/296,294 US7361748B2 (en) | 2001-04-25 | 2005-12-08 | von Willebrand factor (vWF)—cleaving protease |
US12/103,899 US8067221B2 (en) | 2001-04-25 | 2008-04-16 | Von Willebrand factor (vWF)-cleaving protease |
US13/271,761 US20130041137A1 (en) | 2001-04-25 | 2011-10-12 | von Willebrand Factor (vWF) - Cleaving Protease |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-128342 | 2001-04-25 | ||
JP2001128342 | 2001-04-25 | ||
JP2001227510 | 2001-07-27 | ||
JP2001-227510 | 2001-07-27 | ||
JP2001302977 | 2001-09-28 | ||
JP2001-302977 | 2001-09-28 | ||
JP2002017596 | 2002-01-25 | ||
JP2002-017596 | 2002-01-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10475538 A-371-Of-International | 2002-04-25 | ||
US11/296,294 Division US7361748B2 (en) | 2001-04-25 | 2005-12-08 | von Willebrand factor (vWF)—cleaving protease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002088366A1 true WO2002088366A1 (fr) | 2002-11-07 |
Family
ID=27482239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004141 WO2002088366A1 (fr) | 2001-04-25 | 2002-04-25 | Enzyme de clivage du facteur de von willebrand (vwf) |
Country Status (13)
Country | Link |
---|---|
US (4) | US7112666B2 (ja) |
EP (2) | EP1391516A4 (ja) |
JP (3) | JP2003284570A (ja) |
KR (1) | KR101047604B1 (ja) |
CN (2) | CN100537770C (ja) |
AT (1) | ATE525471T1 (ja) |
AU (2) | AU2008201773B2 (ja) |
CA (1) | CA2445421C (ja) |
CY (1) | CY1112000T1 (ja) |
DK (1) | DK1956093T3 (ja) |
ES (1) | ES2373482T3 (ja) |
PT (1) | PT1956093E (ja) |
WO (1) | WO2002088366A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029242A1 (ja) * | 2002-09-25 | 2004-04-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系 |
WO2009001743A1 (ja) | 2007-06-22 | 2008-12-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 新規adamts-13改変体 |
US8623352B2 (en) | 2009-09-21 | 2014-01-07 | Baxter International Inc. | Stabilized liquid and lyophilized ADAMTS13 formulations |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016492A2 (en) * | 2001-08-16 | 2003-02-27 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
ATE486936T1 (de) * | 2003-03-05 | 2010-11-15 | Chemo Sero Therapeut Res Inst | Verfahren zur herstellung eines heterologen proteins in e. coli |
WO2004083250A1 (ja) * | 2003-03-17 | 2004-09-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物 |
US8088624B2 (en) | 2003-12-22 | 2012-01-03 | Mitsubishi Kagaku Iatron, Inc. | Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease |
US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
US20080138837A1 (en) * | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
EP1852442B1 (en) * | 2005-02-14 | 2012-03-14 | Alfresa Pharma Corporation | Antibody for assay of adamts13 activity and method of activity assay |
PL1902141T3 (pl) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
JP5067917B2 (ja) * | 2005-12-28 | 2012-11-07 | アルフレッサファーマ株式会社 | Adamts13の分離精製方法 |
FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
US20090317375A1 (en) * | 2008-05-12 | 2009-12-24 | Immune Disease Institute, Inc. | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
EP3388529A1 (en) * | 2008-12-05 | 2018-10-17 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
US8759293B2 (en) * | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
WO2015021552A1 (en) * | 2013-08-14 | 2015-02-19 | National Research Council Of Canada | Clipped amplifier |
JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
EP3526339A1 (en) | 2016-10-11 | 2019-08-21 | Laboratory Corporation of America Holdings | Methods and systems for determining adamts13 enzyme activity |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
WO2020214033A1 (en) * | 2019-04-17 | 2020-10-22 | Erasmus University Medical Center Rotterdam | Papain-like cysteine peptidase medicaments and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508918A (ja) * | 1996-04-29 | 2000-07-18 | イムノ・アクチエンゲゼルシャフト | 精製されたマルチメラーゼ |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4437544A1 (de) | 1994-10-20 | 1996-04-25 | Behringwerke Ag | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
JP4451514B2 (ja) | 1999-08-24 | 2010-04-14 | 財団法人化学及血清療法研究所 | 血液凝固第vii因子改変体 |
US20010049106A1 (en) * | 2000-04-27 | 2001-12-06 | Leonard Buckbinder | ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
AU2002218196A1 (en) * | 2000-09-28 | 2002-04-08 | Bayer Aktiengesellschaft | Regulation of human adam-ts-like protein |
US20020151702A1 (en) * | 2000-10-18 | 2002-10-17 | Genetics Institute, Inc. | Aggrecanase molecules |
US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
DE60331666D1 (de) * | 2002-09-25 | 2010-04-22 | Chemo Sero Therapeut Res Inst | Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon |
-
2002
- 2002-04-24 JP JP2002123103A patent/JP2003284570A/ja not_active Withdrawn
- 2002-04-25 ES ES08156811T patent/ES2373482T3/es not_active Expired - Lifetime
- 2002-04-25 PT PT08156811T patent/PT1956093E/pt unknown
- 2002-04-25 AT AT08156811T patent/ATE525471T1/de active
- 2002-04-25 CN CNB028127579A patent/CN100537770C/zh not_active Expired - Lifetime
- 2002-04-25 DK DK08156811.5T patent/DK1956093T3/da active
- 2002-04-25 US US10/475,538 patent/US7112666B2/en not_active Expired - Lifetime
- 2002-04-25 JP JP2002585646A patent/JP4163517B2/ja not_active Expired - Lifetime
- 2002-04-25 EP EP02722783A patent/EP1391516A4/en not_active Ceased
- 2002-04-25 CN CN200910165592A patent/CN101613688A/zh active Pending
- 2002-04-25 KR KR1020037014013A patent/KR101047604B1/ko active IP Right Grant
- 2002-04-25 EP EP08156811A patent/EP1956093B1/en not_active Expired - Lifetime
- 2002-04-25 WO PCT/JP2002/004141 patent/WO2002088366A1/ja active Application Filing
- 2002-04-25 CA CA2445421A patent/CA2445421C/en not_active Expired - Lifetime
-
2005
- 2005-12-08 US US11/296,294 patent/US7361748B2/en not_active Expired - Lifetime
-
2007
- 2007-12-28 JP JP2007338732A patent/JP2008109938A/ja active Pending
-
2008
- 2008-04-16 US US12/103,899 patent/US8067221B2/en not_active Expired - Fee Related
- 2008-04-22 AU AU2008201773A patent/AU2008201773B2/en not_active Expired
- 2008-11-17 AU AU2008243279A patent/AU2008243279B2/en not_active Expired
-
2011
- 2011-10-12 US US13/271,761 patent/US20130041137A1/en not_active Abandoned
- 2011-11-11 CY CY20111101087T patent/CY1112000T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508918A (ja) * | 1996-04-29 | 2000-07-18 | イムノ・アクチエンゲゼルシャフト | 精製されたマルチメラーゼ |
Non-Patent Citations (1)
Title |
---|
MIHA FURLAN ET AL.: "Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotis thrombocytopenic purpura", BLOOD, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2839 - 2846, XP002953592 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013078319A (ja) * | 2002-09-25 | 2013-05-02 | Chemo-Sero-Therapeutic Research Inst | フォンビルブランド因子特異的切断酵素を主成分とする診断薬および医薬品 |
WO2004029242A1 (ja) * | 2002-09-25 | 2004-04-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系 |
US7575872B2 (en) | 2002-09-25 | 2009-08-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Antibody against von Willebrand factor cleaving enzyme and assay system using the same |
EP2157178A1 (en) | 2002-09-25 | 2010-02-24 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Antibody against von Willebrand Factor cleaving enzyme and assay system using the same |
EP2759593A1 (en) | 2007-06-22 | 2014-07-30 | The Chemo-Sero-Therapeutic Research Institute | Novel ADAMTS-13 mutant |
EP2374878A2 (en) | 2007-06-22 | 2011-10-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Novel adamts-13 mutant |
US8685665B2 (en) | 2007-06-22 | 2014-04-01 | The Chemo-Sero-Therapeutic Research Institute | ADAMTS-13 mutant |
WO2009001743A1 (ja) | 2007-06-22 | 2008-12-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 新規adamts-13改変体 |
US8906661B2 (en) | 2007-06-22 | 2014-12-09 | The Chemo-Sero-Therapeutic Research Institute | ADAMTS-13 mutant |
US9109217B2 (en) | 2007-06-22 | 2015-08-18 | The Chemo-Sero-Therapeutic Research Institute | ADAMTS-13 mutant |
US8623352B2 (en) | 2009-09-21 | 2014-01-07 | Baxter International Inc. | Stabilized liquid and lyophilized ADAMTS13 formulations |
US9351935B2 (en) | 2009-09-21 | 2016-05-31 | Baxalta Incorporated | Stabilized liquid and lyophilized ADAMTS13 formulations |
US9572778B2 (en) | 2009-09-21 | 2017-02-21 | Baxalta Incorporated | Stabilized liquid and lyophilized ADAMTS13 formulations |
US9937244B2 (en) | 2009-09-21 | 2018-04-10 | Baxalta Incorporated | Stabilized liquid and lyophilized ADAMTS13 formulations |
US10238720B2 (en) | 2009-09-21 | 2019-03-26 | Baxalta Incorporated | Stabilized liquid and lyophilized ADAMTS13 formulations |
US10758599B2 (en) | 2009-09-21 | 2020-09-01 | Baxalta Incorporated | Stabilized liquid and lyophilized ADAMTS13 formulations |
US11564979B2 (en) | 2009-09-21 | 2023-01-31 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
Also Published As
Publication number | Publication date |
---|---|
EP1391516A4 (en) | 2004-07-14 |
AU2008243279A1 (en) | 2008-12-04 |
ATE525471T1 (de) | 2011-10-15 |
CN1537167A (zh) | 2004-10-13 |
AU2008201773A1 (en) | 2008-05-15 |
US20080254527A1 (en) | 2008-10-16 |
JP2008109938A (ja) | 2008-05-15 |
EP1956093B1 (en) | 2011-09-21 |
US7112666B2 (en) | 2006-09-26 |
US7361748B2 (en) | 2008-04-22 |
ES2373482T3 (es) | 2012-02-03 |
AU2008201773B2 (en) | 2008-12-18 |
CN100537770C (zh) | 2009-09-09 |
JP4163517B2 (ja) | 2008-10-08 |
CA2445421C (en) | 2012-08-07 |
JPWO2002088366A1 (ja) | 2004-08-19 |
US20060073569A1 (en) | 2006-04-06 |
AU2008243279B2 (en) | 2012-06-14 |
CA2445421A1 (en) | 2002-11-07 |
KR101047604B1 (ko) | 2011-07-07 |
AU2008201773A8 (en) | 2008-05-22 |
US8067221B2 (en) | 2011-11-29 |
DK1956093T3 (da) | 2012-01-16 |
CY1112000T1 (el) | 2015-11-04 |
PT1956093E (pt) | 2011-12-30 |
CN101613688A (zh) | 2009-12-30 |
EP1391516A1 (en) | 2004-02-25 |
US20130041137A1 (en) | 2013-02-14 |
JP2003284570A (ja) | 2003-10-07 |
US20040214275A1 (en) | 2004-10-28 |
KR20040015163A (ko) | 2004-02-18 |
EP1956093A1 (en) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002088366A1 (fr) | Enzyme de clivage du facteur de von willebrand (vwf) | |
US9309506B2 (en) | Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV | |
EA028865B1 (ru) | Модифицированные полипептиды фактора х и их применение | |
WO1992000325A1 (en) | Anticoagulant polypeptides | |
KR20070036057A (ko) | 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체 | |
US20210299178A1 (en) | Methods of using dnase1-like 3 in therapy | |
AU2012207034A1 (en) | Von Willebrand factor (vWF) - cleaving protease | |
AU774591B2 (en) | Novel molecules | |
JP2002085059A (ja) | 新規なtsp1ドメイン含有ポリペプチド | |
JP2005046135A (ja) | イヌフォリスタチンおよびその製造方法 | |
ZA200304741B (en) | Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide. | |
JP2002176994A (ja) | ヒトabh |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10475538 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002585646 Country of ref document: JP Ref document number: 2445421 Country of ref document: CA Ref document number: 1020037014013 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002253593 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002722783 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028127579 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002722783 Country of ref document: EP |